Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization

1 Jan 2020

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is a novel beta coronavirus. SARS-CoV-2 uses spike glycoprotein to interact with host angiotensin-converting enzyme 2 (ACE2) and ensure cell recognition. High infectivity of SARS-CoV-2 raises questions on spike-ACE2 binding affinity and its neutralization by anti-SARS-CoV monoclonal antibodies (mAbs)....

Topics

Join the communities discussing this publication.

COVID-19 Clinical Research Studies
Influenza Virus Research Studies
SARS-CoV-2 and COVID-19 Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33200028
DOI: 10.1016/j.csbj.2020.11.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralizationPMID 33200028Read ↗

Sequence variation of SARS-CoV-2 spike protein may facilitate stronger interaction with ACE2 promoting high infectivitySemantic proximity Read ↗

The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and AntibodiesSemantic proximity Read ↗

Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein.Semantic proximity Read ↗

Structural perspective of the interactions of ACE2 and SARS CoV-2 Spike protein RBDSemantic proximity Read ↗

SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infectionSemantic proximity Read ↗

ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodiesSemantic proximity Read ↗

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.Semantic proximity Read ↗

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read ↗

Spike Glycoprotein-Mediated Entry of SARS CoronavirusesSemantic proximity Read ↗

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodiesSemantic proximity Read ↗

Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodiesSemantic proximity Read ↗

D614G mutation of SARS-CoV-2 spike protein enhances viral infectivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.